title: Cinnarizine and dimenhydrinate in the treatment of vertigo in medical practice.
abstract: The efficacy and safety of the fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg in the treatment of vertigo of various origins have been investigated in a prospective, noninterventional study involving private practices throughout Germany. A total of 1275 patients with an average age of 61.2 years participated in the study. The vertigo symptoms, measured by a validated mean vertigo score (primary efficacy endpoint) improved by 61 % in the course of the observational period (median: 6 weeks). Concomitant symptoms frequently associated with vertigo such as nausea, vomiting and tinnitus were also markedly reduced by 84, 85 and 51 %, respectively. Overall efficacy has been rated by the physicians as 'very much improved' or 'much improved' in 95 % of the patients. A total of 47 patients (3.7 %) reported 51 adverse drug reactions (all nonserious). The results indicate a good tolerability and efficacy of the fixed combination of cinnarizine and dimenhydrinate in the treatment of vertigo in daily medical practice, which is in line with previous findings of numerous interventional, randomised, double-blind, controlled clinical trials.
authors.affiliation: Department of Otorhinolaryngology, Division of Neurotology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. arne.scholtz@i-med.ac.at.
authors.forename: Arne-Wulf
authors.initials: AW
authors.lastname: Scholtz
authors.affiliation: Department of Oto-Laryngology and Plastic Head and Neck Surgery, University Hospital Aachen, Aachen, Germany.
authors.forename: Justus
authors.initials: J
authors.lastname: Ilgner
authors.affiliation: Department of Otorhinolaryngology, Head and Neck Surgery, Rudolfstiftung Tertiary Teaching Hospital, Vienna, Austria.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Loader
authors.affiliation: Medical Department, Hennig Arzneimittel, Floersheim am Main, Germany.
authors.forename: Bernd W
authors.initials: BW
authors.lastname: Pritschow
authors.affiliation: Medical Department, Hennig Arzneimittel, Floersheim am Main, Germany.
authors.forename: Gerhard
authors.initials: G
authors.lastname: Weisshaar
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000932:Antiemetics / Q000627:therapeutic use; D002936:Cinnarizine / Q000627:therapeutic use*; D004111:Dimenhydrinate / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology* / Q000517:prevention & control*; D005260:Female; D005858:Germany / Q000453:epidemiology; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012307:Risk Factors; D017678:Sex Distribution; D016896:Treatment Outcome; D014717:Vertigo / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D055815:Young Adult
chemical_list: D000932:Antiemetics; D006634:Histamine H1 Antagonists; D002936:Cinnarizine; D004111:Dimenhydrinate
keywords: Cinnarizine; Dimenhydrinate; Fixed combination; Noninterventional study; Vertigo